Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...
A molecular subtype–guided, chemotherapy-free neoadjuvant strategy using SHR-A1811 plus pertuzumab for hormone receptor–positive/HER2-positive breast cancer: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results